NCT07763821Not yet recruiting
Clinical Utility of Serum Ribonuclease 1(RNASE1) as a Biomarker of Lupus Nephritis.
Source: ClinicalTrials.gov · Last updated 13 Aug 2026
Brief summary (registry, in English)
This study will identify the level of serum Riboneuclease 1 in systemic lupus patients and compare between its level in lupus nephritis and non nephritis.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 128 (estimated)
- First submitted
- 9 Aug 2026
- Start date
- 30 Sept 2026
- Primary completion date
- 30 Sept 2027
- Lead sponsor
- Assiut University
- Diseases
- Lupus (SLE)
- NCT number
- NCT07763821
What you commit to
- Study type: Observational
- Planned participants: 128
- From 30 Sept 2026 to the primary completion date, 30 Sept 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with other autoimmune diseases
- Active infection and malignancy
Age
- Patients less than 18 years old
Other
- Pregnancy and lactation
- Inability to provide informed consent
Who the study is looking for
- Adult patients (≥18 years old) with non lupus nephritis SLE diagnosed according to the 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus .
- Adult patients (≥18 years old) with Lupus Nephritis classified according to the 2018 ISN/RPS classification criteria.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.